NeuroSearch publishes promising meta-analysis of Huntexil studies
This article was originally published in Scrip
Executive Summary
NeuroSearch, the Danish CNS-focused biotech, has published the results of a meta-analysis of pooled datasets from two previous trials – the Phase IIb HART and Phase III MermaiHD studies -- corroborating earlier conclusions that Huntexil (pridopidine), 45 mg twice daily, has potential to treat Huntington's disease. NeuroSearch intends to include the results of the meta-analysis in the clinical data package on Huntexil, which the company plans to present to and discuss with US and European regulators during the first half of 2011.